Repros Therapeutics — Investor Presentation (August 2014)
28 slides from Repros Therapeutics's investor presentation, Aug 20, 2014
Slide 1: Androxal: A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism
Androxal ® A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism
Slide 2: Repros Disclaimer
Repros Disclaimer Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertai
Slide 3: Hypogonadism Background: Normal HPT Axis
Hypogonadism Background Normal Hypothalamus - Pituitary - Testes (HPT) Axis A. Normal secretion of LH and FSH B. Normal stimulation of testes C. Results in normal testosterone levels and sperm production Seftel A. Male hypogonadism . Part II: etiology, pathophysiology , and diagnosis. Int J Impot Re
Slide 4: Hypogonadism Background Overview
Hypogonadism Background • Hypogonadism is a condition in which a male is unable to produce sufficient testosterone (T) . • A man is considered to be clinically hypogonadal if his morning testosterone is < 300 ng / dL (normal range 300 - 1040 ng / dL ). • In a recent study, hypogonadism was estimated
Slide 5: Hypogonadism Background: Primary Hypogonadism
Hypogonadism Background • The less frequent type is primary , which is typically a result of a genetic defect, trauma or viral infections such as mumps. • This type of disorder is easily diagnosed by assessing both testosterone and the pituitary hormone that drives testicular synthesis of testostero
Slide 6: Hypogonadism Background: Secondary Hypogonadism
Hypogonadism Background • The more common dysfunction is secondary hypogonadism (85 - 95% of hypogonadal men). • This dysfunction is characterized by low testosterone and low/low normal LH and is a result of the pituitary not responding to the low T state by secreting more LH to drive T synthesis. •
Slide 7: Primary vs Secondary Hypogonadism
Primary vs Secondary Hypogonadism Guay A et al. Int J Impot Res 22:9 - 19, 2011 . 0 10 20 30 40 50 <40 40-60 >60 Percentage Primary Secondary age groups (years) “The prevalence of secondary hypogonadism is far greater than that of primary hypogonadism .”
Slide 8: Incidence and Type of Hypogonadism: European Male Aging Study
Incidence and Type of Hypogonadism European Male Aging Study Distribution and Selected Characteristics of Men Ages 40 - 79 ( Tajar et al) 0 10 20 30 40 50 60 70 80 90 100 Eugonadal Secondary Hypogonadal Primary Compensated Hypogonadism % of Subjects % of Subjects Age: 58.5 (10.7) BMI: 27.3 TT: 513.4
Slide 9: Weight Effect on T Production in the Secondary Hypogonadal Male
• A man’s weight affects his T level more than his age. • Obese men, at even a young age, experience obesity - related Low T. • Weight loss significantly improves T levels in the secondary hypogonadal male. • The secondary hypogonadal male has functional but under - stimulated testes due to obesity
Slide 10: BMI Distribution in Study of Secondary Hypogonadism, ZA-003
BMI Distribution in Study of Secondary Hypogonadism , Repros : ZA - 003 (% of Subjects) 0 10 20 30 40 50 60 70 80 90 100 Underweight <18.5 Normal 18.5-24.9 Overweight 25-29.9 Obese>30 Weight Classification of Subjects Enrolled in ZA - 003 (n=204) Screening Criteria: T<300 ng/dL
Slide 11: The Average American Male at All Ages Was Overweight in 2000
The Average American Male at All Ages Was Overweight in 2000 Overweight BMI > 25 (6’ 190# male BMI=25.8) Obese BMI > 30 (6’ 230# male BMI =31.2) In 2010 there were ~90 million men in the US between the ages of 20 and 65 32% are obese
Slide 12: Hypogonadism Background: Secondary Hypogonadism Mechanism
Hypogonadism Background Secondary Hypogonadism • Decreased secretion of LH (and FSH), caused by an abnormality in the anterior pituitary, leads to under stimulation of potentially normal testes. • When secondary hypogonadism is caused by hypothalamic dysfunction, secretion of gonadotropin - releasin
Slide 13: ZA-304 & 305 Testosterone Baseline Data
ZA - 304 & 305 Testosterone Baseline Data Consistent with Study Inclusion/Exclusion Criteria ZA - 305 Baseline Morning T (fully enrolled, n=127) Mean Age: 47 Mean BMI: 33.4 Morning T (ng/ dL ) Mean 216.2 Median 214.0 Standard Deviation 54.1 (Minimum, Maximum) (79.0,299.0) ZA - 304 Baseline Morning T
Slide 14: ZA-304 & 305 Sperm Baseline Data
ZA - 304 & 305 Sperm Baseline Data Consistent with Study Inclusion/Exclusion Criteria 0 2 4 6 8 10 12 14 16 18 20 22 24 <15 25 35 45 55 65 75 85 95 100 150 200 250 more Number of Subjects per Interval Mean Sperm Concentration (10 6 /mL) ZA - 305 Baseline Sperm Concentration Histogram 0 2 4 6 8 10 12
Slide 15: Initial Screening Findings for ZA-304 & 305
Initial Screening Findings for ZA - 304 & 305 Age ≤ 60, BMI > 25 Category Number of Men Age Mean ( StDev ) T ng/ dL ** Mean ( StDev ) BMI Mean ( StDev ) Total Screened 642 47.5 (8.6) 267 (83.6) 33.3 (4.6) Randomized 256 47.3 (8.3) 237 (43.8) 33.4 (4.4) Screen Failed 386 BMI>42 2 48 (5.7) - - Eye Exa
Slide 16: Overweight Men Exhibit Lower Than Normal T Compared to Age Matched Controls
Overweight Men Exhibit Lower Than Normal T Compared to Aged Matched Controls 0 10 20 30 40 50 60 70 80 90 <300 300-350 350-400 400-450 450-500 >500 Distribution of Morning T for Men Screen Failing Due to High T Mean Age: 46.3 100 200 300 400 500 600 700 800 900 Framingham Heart Study 40-49 Framingha
Slide 17: Day to Day Morning T Variability in the Secondary Hypogonadal Male
Day to Day Morning T Variability in the Secondary Hypogonadal Male Sampling of Placebo Subjects ZA - 003 Overtime: Over 50% of men in placebo arms exhibit normal T in 6 month studies Approximately 25% of men in placebo arms exhibit normal T in 3 month studies
Slide 18: So Why Not Just Give Secondary Hypogonadal Men Testosterone?
So Why Not Just Give Secondary Hypogonadal Men Testosterone? • Unlike primary testicular failure, secondary hypogonadal men still have functional testes but their pituitary does not secrete appropriate levels of hormones to stimulate testicular function • Over time these men exhibit “ normal ” T unl
Slide 19: Androxal Improves Pituitary-Testes Signaling
Androxal Improves Pituitary - Testes Signaling Testosterone Replacement Suppresses Pituitary Responsiveness and Testicular Function p - value < 0.0001
Slide 20: % of Subjects with FSH Below Lower Limit of Normal after 3 Months
% of Subjects with FSH Below the Lower Limit of Normal and Below the Lower Limit of Detection (0.3 mIU/ml) after 3 months ZA - 003 “Completer” Analysis
Slide 21: Head to Head Comparison of Androxal to Testim and Placebo, ZA-203
Head to Head Comparison of Two Doses of Androxal to Testim and Placebo, Study ZA - 203 An approved T gel significantly suppresses LH and FSH in a clinically relevant manner and suppresses sperm concentration to near severe oligospermia (median sperm concentration 6.2 million/mL) after only three mon
Slide 22: Testosterone Replacement Induces Hormone Dependence in 6 Week Study
ZA - 204 Testosterone Replacement Induces Hormone Dependence in the Secondary Hypogonadal Male in 6 Week Exposure Study 0 100 200 300 400 500 600 Baseline End of Study End of Study +1 Week Mean Morning Testosterone (ng/ dL ) Androxal Androgel N = 31 Mean =263 StDev =88.7 N = 14 Mean =248 StDev =74.2
Slide 23: Influence of Prior Testosterone, ZA-300
Influence of Prior Testosterone ZA - 300, 6 month study
Slide 24: Androxal Safety
Androxal Safety • Generally well tolerated at all doses – > 1500 men exposed – > 900 men for 6 months – > 150 men for 12 months – > 700 patient years of exposure • Adverse events consistent with increasing T – No exposure of T outside the normal range • Lower frequency of increased hematocrit 0 1 2
Slide 25: ZA-Hour Assessment Androgel 1%
ZA - 204 24 Hour Assessment Androgel 1% 0 500 1000 1500 2000 2500 3000 0 5 10 15 20 Total Testosterone Hours Some Subjects in Androgel Arm Exhibited T>1040
Slide 26: Androxal Exhibits Unique Profile vs Approved Hormone Replacement
Androxal Exhibits Unique Profile with Numerous Advantages vs Approved Hormone Replacement • The Androxal Advantages – Oral – Not controlled substance, cannot be abused – Less CV risk than T’s??? • No supernormal levels of T achieved – No transference risk – Restores normal function (no loss of testi
Slide 27: Upcoming Androxal Related Events
Upcoming Androxal Related Events • ZA - 305 Last Patient Last Visit 8/22/14 • Anticipated Release of 305 Data Mid 9 - 14 • FDA AdCom Meeting 9/17/14 • Anticipated Release of 304 Data Mid 10 - 14 • NYC Analyst Day Morning of Halloween • Submit Androxal NDA Around Year - end ‘14
Slide 28: Financial Summary
Financial Summary • Cash and equivalents (as of 7/31/14, unaudited) $57.5 M • Cash runway: Through 2016* – Anticipate Androxal approved and launched • Current shares outstanding: 23.1 M shares – Warrants Outstanding – Series A – 877,137 (purchased in unit deal @ $2.45); Series B – 809,704 @ $2.49 ex
Repros Therapeutics — Investor Presentation (August 2014) on 6ix